Kyriakides Georgopoulos has advised Novartis on the separation of its Sandoz generic and biosimilars division in Greece.
According to KG, "the local transaction was part of the global separation and spin-off of Sandoz, which was completed on October 4, 2023. As a consequence, Sandoz has become an independent, publicly traded company on the SIX Swiss Exchange with ADRs traded on the over-the-counter market in the US. The local transaction was completed on February 1, 2024, from which date onwards Sandoz Hellas Single Member shall market the generic and biosimilar products of Sandoz in the Greek market."
The KG team included Partner Claire Pavlou, Counsel Katerina Tzamalouka, and Associate Aggelos Kosteletos.
KG did not respond to our inquiry on the matter.